Buradasınız

Anasayfa » Content

ANTİFOSFOLİPİD SENDROMU OLAN BİR HASTADAN MONOKLONAL ANTİ-p2 GLİKOPROTEİN ANTİKORLARININ ÜRETİLMESİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2001
Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The production of monoclonal anti-01 glycoprotein I antibodies from palient with antiphosp-holipid syndrome. The production of monoclonal anti-p2 glycoprotein I antiboies from patient with antip Recurrent arterial or venous thrombosis and/or fetal loss with positive tests for an-tiphospholipid (aPL) autoantibodies has been classified as the antiphospholipid syndrome (APS). It has been found that most aPL antibodies in patients with APS do not bind exclusi-vely to phospholipid antigens but react with protein cofactor-phospholipid antigen complexes. These protein cofactors were found to be plasma proteins like p2-glycoprotein (P2GPI) and prothrombin . Although investigations revealed the importance of anti-p2GPI antibodies in the pathogenesis of APS, the origin of these autoantibodies and mechanisms of their pathogenicity could not be explained completely. In this study, B-cells from a spleen of a patient with APS were used in a fusion experiment in order to produce monoclonal anti-(2GPI antibody secre-ting hybridomas. Two different autoantibody secreting hybridomas were produced. The monoclonal autoantibodies bind to both cardiolipin and p2GPI.
Bookmark/Search this post with
Abstract (Original Language): 
Tekrarlayan arter veya ven trombozları ve /veya fetus kayıpları ile birlikte antifosfolipid antikorların (AFLA) saptanması antifosfolipid sendromu (AFS) olarak tanımlanmıştır. AFS'li hastalarda saptanan AFLA'ların önemli bir bölümünün sadece fosfolipidlere değil p2-glikoprotein (p2GPI) ve protrombin başta olmak üzere plazma proteini içeren ve protein kofaktör-fosfoli-pid'den oluşan antijen komplekslerine bağlandığı ortaya konmuştur Yapılan araştırmalar anti-p2GPI antikorların AFS patogenezindeki önemini belirlemekle birlikte, bu otoantikorlarm ortaya çıkışlarının ve patojenik etkilerinin mekanizmaları tam olarak açıklanamamıştır. Bu çalışmada AFS'li bir hastanın dalağından elde edilen B-hücreleri kullanılarak yapılan füzyon deneyi ile hibridoma oluşturularak monoklonal anti-p2GPI elde edilmesi amaçlanmıştır. Kardiyoli-pin ve p2GPI'e bağlanlanan monoklonal otoantikor üreten iki hibridoma üretilmiştir
FULL TEXT (PDF): 
PDF icon arastirmax-antifosfolipid-sendromu-olan-bir-hastadan-monoklonal-anti-p2-glikoprotein-antikorlarinin-uretilmesi.pdf
  • 4
285-289
  • Turkish

REFERENCES

References: 

1. Alarcon-Segovia D, Cabral AR: The antiphospholi-pid/cofactor syndromes. J Rheumatol 23:1319 (1996).
2. Asherson RA, Cervera R: Primary, secondary and other variants of the antiphospholipid syndrome. Lupus 3:293 (1994).
3. Casali P, Notkins AL: Probing the B celi repertoire with EBV.: polyreactive antibodies and CD5+ B lymphocytes. Ann Rev Immunol 7:513 (1989).
4. Ehrenstein MR, Leaker B, Isenberg D, Cambridge G: Production of hunıan monoclonal antibodies to myelope-roxidase. Immunology 76:617 (1992).
5. Ehrenstein M, Longhurst C, Isenberg DA: Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 92:39(1993).
6. Ehrenstein MR: Production and analysis of human monoclonal
IgG anti-DNA antibodies. PhD Thesis University College London, Londra, İngiltere (1994).
7. Galü M, Bevers EM: Inhibition of phospholipid depen-dent coagulation reactions by antiphospholipid antibodies : possible mode of action. Lupus 3:223 (1994).
8. Grunovv R, Jahn S, Portsmann T, Kiessig SS ve ark: The higher efficiency, human B celi immortalising heterom-yelomaCB-F7. J Immunol Methods 106:257 (1988).
9. Hughes GRV: The antiphospholipid syndrome : ten years on. Lancet 342:341 (1993).
10. İnanç M: Sistemik lupus eritematozusta antikardiyolipin antikorların ve antifosfolipid sendromunun klinik öneminin araştırılması. Romatoloji Yandal Uzmanlık Tezi, İstanbul Tıp Fakültesi (1996).
11. İnanç M, Rad\vay-Bright EL, Isenberg DA. p2-glycopro-tein I/anti- (32-giycoprotein I: Where are we novv? (Scien-tific Review). Br J Rheumatol 36; 1247 (1997).
12. İnanç M, Donohoe S, Ravirajan C, Radway-Bright EL, Mackie I, Machin S, Isenberg DA: Anti-p2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with SLE and antiphospholipid syndrome. BrJ Rheumatol 37:1089 (1998).
13. Küçükkaya-Diz R, Hacıhanefioğlu A, Yenerel M, Turgut M, Keskin H, Nalçacı M, İnanç M: Antiphospholipid antibodies and antiphospholipid syndrome in patients pre-senting vvith immune thrombocytopenic purpura: a pros-pective cohort study. Blood 98:1760 (2001).
14. Lieby P, Soley A, Levallois H, ve ark. The clonal analysis of anticardiolipin antibodies in a single patient vvith primary antiphospholipid syndrome revals an extreme antibody heterogeneity. Blood 97:3820 (2001).
15. Menon S, Rahman MAA, Ravirajan CT ve ark. The production, binding characteristics and sequence analysis of four human IgG monoclonal antiphospholipid antibodies. J Autoimmun 10:43 (1997).
16. Radvvay-Bright EL, İnanç M, Isenberg DA. Animal mo-dels of the antiphospholipid syndrome. Rheumatology 38:591(1999).
17. Ravirajan CT, Harmer I, McNally T, Hohmann A, Mack-vvorth-Young CG, Isenberg DA. Phospholipid binding specificities and idiotype expression of hybridoma deri-ved monoclonal autoantibodies from splenic cells of patients vvith sytemic lupus erythematosus. Ann Rheum Dis 54:471 (1995).
18. Wang M, Kandiah DA, Ichikavva K ve ark. Epitope spe-cificity of monoclonal anti-p2-glcoprotein I antibodies derived from patients vvith the antiphospholipid syndrome. J Immunol 155:1629 (1995).

Thank you for copying data from http://www.arastirmax.com